공지 • Dec 19
Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022
Genscript Biotech Corporation announced redesignation of Dr. Zhang Fangliang from a non-executive Director to an executive Director with effect from December 17, 2022. Dr. Zhang will be responsible for the overall strategic development and planning, the risk management, and the investments, mergers and acquisitions of the Group in order to meet the requirements of achieving the rapid growth and improving the core competencies of the Group. Dr. Zhang Fangliang, aged 58, is the co-founder and a non-executive Director of the Company before the redesignation. He was appointed as a Director on 21 May 2015, redesignated as an executive Director and appointed as chairman of the Board on 24 August 2015, redesignated from an executive Director to a non-executive Director on 2 August 2020, resigned from a non- executive Director and chairman of the Board on 22 November 2020, reappointed as a non- executive Director, appointed as chairman of the risk management committee of the Board and chairman of the strategy committee of the Board on 2 May 2022, and redesignated from a non- executive Director to an executive Director on 17 December 2022. As our executive Director, he is primarily responsible for the overall strategic development and planning, the risk management, and the investments, mergers and acquisitions of the Group. He is one of the founders and a director of Genscript Corporation. He was a director and chairman of our non-wholly-owned subsidiary Legend Biotech Corporation from 27 May 2015 to 22 November 2020 and was its chief executive officer from 2 August 2020 to 22 November 2020. He was reappointed as a director of Legend Biotech Corporation on 2 August 2022 and was reappointed as chairman of Legend Biotech Corporation on the same day. Dr. Zhang is currently a director of the following members of the Group: GenScript Bioscience (BVI) Limited, Genscript USA Incorporated, GenScript USA Holding Inc., CustomArray Inc., GenScript (Hong Kong) Limited, GenScript Biotech (Singapore) Pte. Ltd., GenScript Biotech (Netherlands) B.V., Bestzyme Biotech Corporation, Bestzyme Biotech Limited, Bestzyme USA Inc., Bestzyme Biotech HK Limited, Bestzyme Hongkong Limited., Bestzyme Biotech Inc., Shandong Bestzyme Biotech Co. Ltd., Yangtze Investment (BVI) Limited, Yangtze Investment USA Inc., Yangtze Holdings (BVI) Limited, Yangtze Investment (HK) Limited, Curegene Biotech Corporation, Curegene Biotech (BVI) Limited, Curegene Biotech (HK) Limited, Novagene Biotech (Cayman) Corporation, Maple Bio (Nanjing) Co. Ltd., and Probio Technology Limited. Dr. Zhang is also the responsible representative of Jinan Bestzyme biological engineering Co. Ltd., Downtown Branch Company. Dr. Zhang has over 25 years of experience in the biotechnology industry. Prior to joining the Group, from 1995 to 2002, he worked as a postdoctoral research fellow and an associate principal scientist at Schering-Plough. Dr. Zhang worked in the tumour biology department during his postdoctoral research at Schering-Plough. Dr. Zhang was also one of the key team members for an anti-cancer drug, farnesyl transferase inhibitor. After Dr. Zhang's postdoctoral studies, he was recruited to the department of central nervous system and cardiovascular system at Schering-Plough. He became one of the project leaders focusing on G-protein coupled receptors and led a group of scientists to discover the drug target for a billion-dollar drug. As a result of this discovery, Dr. Zhang won a Presidential Award at Schering-Plough in 2001. From 2002 to August 2020, Dr. Zhang worked as the chief executive officer of the Company, where he was involved in a variety of key biotechnological research projects and provided guidance and directions to those biotechnological research projects. Dr. Zhang was also awarded the Jiangsu Province High-Level Creative Talent Strategic Award in 2011. Dr. Zhang was awarded as the "Person of the Year" at the China Healthcare Summit 2019. Dr. Zhang obtained a Bachelor of Engineering degree from Chengdu College of Geology (currently known as Chengdu University of Technology) in the PRC in July 1984 and a Master of Science degree from Nanjing University in the PRC in July 1987. He also obtained a Doctor of Philosophy degree from Duke University in the U.S. in September 1995. Dr. Zhang has entered into a service contract (the "Service Contract") with the Company for his role as the executive Director for an initial term of three years commencing from 17 December 2022 and is subject to retirement by rotation and eligible for re-election pursuant to the articles of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Listing Rules"). Pursuant to the Service Contract, Dr. Zhang is entitled to a fixed annual remuneration of US$550,000, which has been recommended by the remuneration committee of the Company and approved by the Board with reference to his duties and responsibilities in the Company and the prevailing market conditions. The appointment letter for the appointment of Dr. Zhang as a non-executive Director entered into between Dr. Zhang and the Company has been terminated by mutual consent with effect from 17 December 2022. As at the date of this announcement, Dr. Zhang held approximately 18.38% of the issued share capital of GenScript Corporation (being the holding company of the Company), and was deemed, or taken to be interested in, all the shares of the Company held by GenScript Corporation for the purpose of the Securities and Futures Ordinance, which in turn GenScript Corporation held 808,577,123 shares of the Company, representing approximately 38.23% of the entire issued share capital of the Company. As at the date of this announcement, Dr. Zhang had interests in 848,329,253 shares of the Company. Save as disclosed above, as at the date of this announcement, Dr. Zhang (i) did not hold any position with the Company or other members of the Group, (ii) did not have any interest in the Company or its associated corporation(s) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), (iii) was independent from and not related to any other Directors, members of senior management, substantial Shareholders or controlling Shareholders (as defined in the Listing Rules), and (iv) had not held any directorship in any listed companies in the last three years preceding the date of this announcement or any other major appointments and professional qualification. Save as disclosed above, there is no matter relating to the re-designation of Dr. Zhang that needs to be brought to the attention of the Shareholders and the Stock Exchange nor any information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.
